Thirteen patients with non-cardiac functional chest pain were randomized to receive 5 mg capsules of dronabinol or placebo twice daily for 4 weeks. Patients described their chest pain episodes, completed the Short Form-36 (SF-36), Beck Anxiety Inventory and Beck Depression Inventory, and rated their pain during esophageal balloon distention tests (EBDT) to determine if dronabinol increased pain thresholds. Results indicate that dronabinol patients had significantly increased pain thresholds during the EBDT for certain pressures compared to baseline and placebo. Beck Anxiety and Depression Inventories and SF-36 were not significantly different between groups, and adverse effects were mild or moderate. A significant percentage of patients in each group were excluded due to noncompliance.